Form 4: Bios Equity COF, LP Reports Beneficial Ownership in Actuate Therapeutics, Inc.

Bios Equity COF, LP, along with related entities and individuals, reports beneficial ownership of Actuate Therapeutics, Inc. common stock as of August 12, 2024.

Summary

• This Form 4 filing reports changes in beneficial ownership of Actuate Therapeutics, Inc. (ACTU) common stock.
• The reporting entities include Bios Equity COF, LP, Bios Clinical Opportunity Fund, LP, BP Directors, LP, and related individuals.
• The filing indicates indirect ownership of common stock through various entities such as Bios Fund I, Bios Fund II, Bios Fund III, and their respective QP and NT variations, as well as Bios Actuate Co-Invest I, II, and III, and Bios 2024 Co-Invest.
• Bios Equity COF, LP is the general partner of Bios Clinical Opportunity Fund, LP and Bios 2024 Co-Invest.
• Cavu Management, LP and Bios Capital Management, LP are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF.
• Leslie W. Kreis and Aaron Fletcher have voting and investment control over shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively.
• Aaron Fletcher disclaims beneficial ownership of shares held in a trust for his children, except to the extent of any pecuniary interest.
• Leslie W. Kreis has sole voting and investment control over shares held by Circle K Invesco, LP.
• This Form 4 is one of six filings related to the same event due to SEC EDGAR system limitations on the number of reporting persons and rows per form.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders, providing transparency to the market regarding the holdings and transactions of key individuals and entities associated with a publicly traded company.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for individuals and entities deemed insiders, such as directors, officers, and significant shareholders (10% owners), in publicly traded companies in the United States.
• These filings are mandated by Section 16(a) of the Securities Exchange Act of 1934 and are overseen by the Securities and Exchange Commission (SEC).
• Similar regulations exist in other countries to ensure transparency and prevent insider trading.
• For example, in the European Union, the Market Abuse Regulation (MAR) requires similar disclosures of transactions by persons discharging managerial responsibilities (PDMRs) and their closely associated persons.
• In Canada, insider reporting requirements are governed by provincial securities laws, such as the Ontario Securities Act, which mandate timely disclosure of insider trades.
• Companies like Berkshire Hathaway, controlled by Warren Buffett, and Tesla, with Elon Musk as CEO, regularly file Form 4s to report changes in their beneficial ownership, setting a benchmark for compliance and transparency in the industry.

Stakeholder Impact

• Shareholders are informed about the ownership structure of the company.
• The filing provides transparency regarding the holdings of significant shareholders.

Key Dates